SecBot SecBot
8-K ·Filed Nov 2, 2026

SIBN

SI-BONE, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed2d 2h ago SEC0001459839-26-000084
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The Q3 beat and reaffirmed guidance are positive, but the key driver is the iFuse Granite Onyx launch and the new MS-DRG reimbursement tailwind that began in October 2026. Monitor the Q4 2026 earnings release for early adoption metrics on Granite Onyx and the revenue impact from the DRG changes, which could accelerate growth into 2027.

DirectionBullish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

SI-BONE reported Q3 2026 revenue of $55.7M, up 14.5% YoY, beating the $55.3M consensus. GAAP net loss per share was -$0.08, improving from -$0.11 a year ago and beating the consensus estimate of -$0.13. The company reaffirmed its full-year 2026 revenue guidance of $231M-$233M and reduced its operating expense growth expectation to 10.5% from 12.0%. Key catalysts include the 510(k) clearance for iFuse Granite Onyx (a $1.5B TAM opportunity) and new MS-DRGs that increase hospital payments for procedures using iFuse Bedrock Granite by up to $50,000 per qualifying procedure.

Key Financial Metrics

EPS
−$0.08
est −$0.13 · +38.5%
Revenue
$55.7M
est $55.3M · +0.7% · +14.5% YoY
Rating
beat
Guidance
$231M-$233M
maintained
Gross Margin
79.3%

Key Facts

  • Q3 2026 worldwide revenue of $55.7M, up 14.5% YoY (beat consensus of $55.3M)
  • GAAP net loss per share of -$0.08, improved from -$0.11 YoY (beat consensus of -$0.13)
  • Adjusted EBITDA of $3.0M, up 32.4% YoY
  • Positive cash from operations of $5.9M, up 154.4% YoY
  • Reaffirmed FY2026 revenue guidance of $231M-$233M (15-16% growth)
  • Reduced FY2026 operating expense growth expectation to 10.5% from 12.0%
  • Received 510(k) clearance for iFuse Granite Onyx, a breakthrough device with $1.5B annual TAM
  • New MS-DRGs effective October 2026 increase hospital payments by up to $50,000 per qualifying iFuse Bedrock Granite procedure
  • Active U.S. physicians grew 16% to 1,770; U.S. procedure volume grew ~19.5%
  • Cash and equivalents of $146.3M as of September 30, 2026

Financial Impact

Revenue beat consensus by $0.4M (0.7%); EPS beat consensus by $0.05 (38.5%); operating expense growth reduced by 1.5 percentage points

revenueepsoperating expensesadjusted EBITDAcash from operations

Segment Breakdown

SegmentRevenueGrowth
U.S.$52.8M+13.9%
International$2.9M+27.0%

Risk Factors

  • Lower average selling price due to procedure mix shift toward office-based and ASC sites of care
  • Gross margin declined slightly to 79.3% from 79.8% due to mix
  • Operating expenses continue to grow (9.7% YoY) driven by sales commissions and new product launches
  • Forward-looking statements subject to risks including tariffs, supply chain, and elective procedure demand

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001459839-26-000084
Document: sibn-20261102.htm0001459839-26-000084
Document: 0001459839-26-000084-index-headers.html0001459839-26-000084
Document: 0001459839-26-000084-index.html0001459839-26-000084
Document: 0001459839-26-000084.txt0001459839-26-000084
8-K Data (Synthetic)0001459839-26-000084
23 reports for SIBN
Performance horizon
100% Hit rate @ T+20 4 of 4 bullish or bearish reports Went positive at some point 5 of 5 best @ T+60▲ +30.50%May 11, 2026
Filters
Rows
Reports for SIBN, sortable and filterable
TypeNow
Nov 4, 2026
today
Insider Cluster
NEUTRAL ★ 3/10
$24.00awaiting T+20awaiting T+20$24.95 (+3.96%)
Nov 4, 2026
today
144
NEUTRAL ★ 2/10
$24.00awaiting T+20awaiting T+20$24.95 (+3.96%)
Nov 4, 2026
today
144
NEUTRAL ★ 3/10
$24.00awaiting T+20awaiting T+20$24.95 (+3.96%)
Nov 4, 2026
today
144
NEUTRAL ★ 3/10
$24.00awaiting T+20awaiting T+20$24.95 (+3.96%)
Nov 2, 2026
2d ago
Insider Cluster
NEUTRAL ★ 3/10
$23.77awaiting T+20awaiting T+20$24.95 (+4.96%)
Nov 2, 2026
2d ago
8-K
BULLISH ★ 6/10
No priceawaiting T+20awaiting T+20No price
Nov 2, 2026
2d ago
Press Release
BULLISH ★ 6/10
$23.77awaiting T+20awaiting T+20$24.95 (+4.96%)
Oct 29, 2026
6d ago
144
NEUTRAL ★ 3/10
$21.23awaiting T+20awaiting T+20$24.95 (+17.52%)
Oct 29, 2026
6d ago
144
NEUTRAL ★ 2/10
$21.23awaiting T+20awaiting T+20$24.95 (+17.52%)
Oct 19, 2026
16d ago
Press Release
NEUTRAL ★ 1/10
$20.54awaiting T+20awaiting T+20$24.95 (+21.47%)
Showing 10 of 23

US Market Status

Market Closed · Opens Thu (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026